Diagnostic value of artificial intelligence-assisted CTA for the assessment of atherosclerosis plaque: a systematic review and meta-analysis.

Background: Artificial intelligence (AI) has increasingly been applied to computed tomography angiography (CTA) images to aid in the assessment of atherosclerotic plaque. Our aim was to explore the diagnostic accuracy of AI-assisted CTA for plaque diagnosis and classification through a systematic review and meta-analysis.

Methods: A systematic literature review was performed by searching PubMed, EMBASE, and the Cochrane Library according to PRISMA guidelines.

Efficacy and Safety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung Cancer.

Purpose: The aim of this study was to evaluate the efficacy and safety of peptide-targeted radionuclide therapy (PTRT) with 177Lu-FAP-2286 in advanced lung cancer.

Patients And Methods: This single-center prospective study included 9 patients diagnosed with advanced lung cancer. These patients met the inclusion criteria and received PTRT with 177Lu-FAP-2286.

Structural characterization and potential anti-tumor activity of a polysaccharide from the halophyte Salicornia bigelovii Torr.

Plant polysaccharides are highly potent bioactive molecules. Clarifying the structural composition and bioactivities of plant polysaccharides will provide insights into their structure-activity relationships. Therefore, herein, we identified a polysaccharide produced by Salicornia bigelovii Torr.

Imaging findings and clinical relevance of Ga-Pentixafor PET in atherosclerosis: a systematic review.

Objective: We aimed to perform a qualitative synthesis of evidence on the role of Ga-Pentixafor PET in atherosclerosis.

Methods: A systematic search of the PubMed and Embase databases for studies reporting the evaluation of atherosclerotic lesions by Ga-Pentixafor PET was performed with a search time frame from database creation to 2022-12-26. The diagnostic test evaluation tool QUADAS-2 was used to evaluate the quality of the included literature and to perform descriptive analyses of relevant outcome indicators.

Preoperative prediction of pancreatic neuroendocrine tumor grade based on Ga-DOTATATE PET/CT.

Objective: To establish a prediction model for preoperatively predicting grade 1 and grade 2/3 tumors in patients with pancreatic neuroendocrine tumors (PNETs) based on Ga-DOTATATE PET/CT.

Methods: Clinical data of 41 patients with PNETs were included in this study. According to the pathological results, they were divided into grade 1 and grade 2/3.

Diagnostic value of F-FDG PET/CT and Ga-FAPI PET/CT in primary liver cancer: A systematic review and meta-analysis.

Objective: To conduct a meta-analysis of the diagnostic efficacy of fluorine-18-fluorodeoxyglucose (F-FDG) and gallium-68-labeled fibroblast-activation protein inhibitor (Ga-FAPI) positron emission tomography/computed tomography (PET/CT) for primary liver cancer based on existing clinical evidence.

Materials And Methods: Meta-analysis was carried out according to PRISMA reporting specification. The clinical studies in PubMed/Medline, Embase and the Cochrane Library database were retrieved from the establishment to September 2022.

Increased 68 Ga-FAPI Activity in Hepatic Inflammatory Myofibroblastoma.

Hepatic inflammatory myofibroblastoma is an uncommon borderline tumor. We present 68 Ga-FAPI PET/CT findings of hepatic inflammatory myofibroblastoma in a 58-year-old man. The rare hepatic inflammatory myofibroblastoma demonstrated intense tracer uptake on 68 Ga-FAPI PET/CT.

Comparison of 68 Ga-DOTATATE PET/CT and 68 Ga-Pentixiafor PET/CT Imaging in a Case of Merkel Cell Carcinoma.

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma with a high rate of metastasis and mortality. We present 68 Ga-DOTATATE PET/CT and 68 Ga-pentixiafor PET/CT findings of MCC in a 62-year-old man. Both 68 Ga-DOTATATE PET/CT and 68 Ga-pentixiafor PET/CT revealed increased radioactive uptake of lesions in the scan range.

68Ga-FAPI PET/CT Imaging of Intracranial Syphilitic Gumma: Comparison to 18F-FDG PET/CT.

Intracranial syphilitic gumma is a rare neurological disease. We present 68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT findings of intracranial syphilitic gumma in a 46-year-old man with HIV. In this case, 68Ga-DOTA-FAPI-04 PET/CT outperforms 18F-FDG in helping to visualizing syphilitic gumma.

Efficacy and safety of Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis.

Objective: To perform a meta-analysis of the efficacy and safety about Lu-DOTATATE therapy for advanced/metastatic pNETs based on the current clinical evidence.

Methods: This systematic review follows the PRISMA guideline. Search PubMed, Medline, EMBASE and CNKI, VIP, Wanfang databases, from establishment to June 2022, on the study of Lu-DOTATATE for advanced/metastatic pNETs, the primary endpoint was to evaluate the treatment effect through DRRs and DCRs.

68Ga-FAPI-04 PET/CT in the Detection of Non-FDG-Avid Solid Pseudopapillary Neoplasm of the Pancreas.

Solid pseudopapillary neoplasm of the pancreas is a rare tumor. A 46-year-old woman presented with chest pain for 6 months. Chest CT revealed a large mass of the right mediastinum.

A systematic review of [Ga]Ga-DOTA-FAPI-04 and [F]FDG PET/CT in the diagnostic value of malignant tumor bone metastasis.

Objective: This study aims to perform a systemic analysis of [Ga]Ga-DOTA-FAPI-04 positron emission tomography (PET)/computerized tomography (CT) and [F]FDG PET/CT for the diagnosis of malignant tumor bone metastasis based on existing clinical evidence.

Methods: This systematic review followed the guidelines of the Preferred Reporting Project (PRISMA) for systematic reviews and meta-analysis. This is a retrospective study of articles published in PubMed.

Elevated 68 Ga-FAPI Uptake by Primary Benign Intraosseous Meningioma.

Intraosseous meningioma is an extremely rare benign tumor. We present the 68 Ga-fibroblast activation protein inhibitor (FAPI) PET/CT findings of primary intraosseous meningioma in a 71-year-old woman. 68 Ga-FAPI PET/CT revealed an intraosseous mass in the right parietal bone with increased FAPI activity.

Comparison of Ga-FAPI and F-FDG PET/CT in the Evaluation of Patients With Newly Diagnosed Non-Small Cell Lung Cancer.

Purpose: Several studies have demonstrated that Ga-FAPI PET/CT shows high intratumoral tracer uptake and low normal tissue uptake, allowing for excellent visualization of cancer. The purpose of this study was to compare the ability of Ga-FAPI and F-FDG PET/CT for the evaluation of newly diagnosed NSCLC.

Materials And Methods: A prospective analysis of 28 individuals with histopathologically newly confirmed NSCLC that underwent Ga-FAPI and F-FDG PET/CT was conducted.

Comparison of 68Ga-FAPI and 18F-FDG PET/CT in Dermatofibrosarcoma Protuberans.

Dermatofibrosarcoma protuberans is a rare soft tissue sarcoma with a high recurrence rate. Herein, we present 68Ga-FAPI and 18F-FDG PET/CT findings of dermatofibrosarcoma protuberans in a 45-year-old man. Dermatofibrosarcoma protuberans only shows limited FDG uptakes on 18F-FDG PET/CT, but demonstrated intense tracer uptakes on 68Ga-FAPI PET/CT.

Intense 68Ga-FAPI Uptake in a Patient With Myositis Ossificans: Mimicking Bone Malignancy.

A 72-year-old man presented with right hip pain, difficulty in walking, and a mass in his right hip for 3 months. CT suggested osteonecrosis of the right femoral head and a mass in the right hip with calcification. A malignancy was suspected, and the patient was subsequently enrolled in the clinical trial of 68Ga-FAPI.

Schmorl Node Can Cause Increased 68Ga-FAPI Activity on PET/CT.

68Ga-FAPI is a newly developed tumor imaging agent with promising clinical applications. However, benign lesions may also show increased FAPI activity. We accidentally discovered that Schmorl node expressed FAPI activity in a patient with sweat gland cancer.

Efficacy and Safety of Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

Objective: To conduct a meta-analysis of the efficacy and safety of Ac-PSMA-617 in the treatment of metastatic castration-resistant prostate cancer based on existing clinical evidence.

Methods: Search for retrospective studies about Ac-PSMA-617 in the treatment of metastatic castration-resistant prostate cancer from establishment to July 2021 in PubMed and EMBASE. The primary endpoint was Ac-PSMA-617 biochemical response evaluation criteria after treatment [any prostate specific antigen (PSA) decrease and PSA decrease >50% from baseline] to evaluate the treatment effect.

Primary Adrenal Sarcomatoid Carcinoma Detected by 18F-FDG PET/CT.

Adrenal sarcomatoid carcinoma is extremely rare. A 53-year-old man was admitted to our hospital due to pain in the upper right abdomen for 1 month. Abdominal CT revealed a huge mass in the right adrenal gland, and a malignancy was suspected.